Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome Prevention - Trial NCT04778787
Access comprehensive clinical trial information for NCT04778787 through Pure Global AI's free database. This Phase 4 trial is sponsored by I.M. Sechenov First Moscow State Medical University and is currently Recruiting. The study focuses on Congestive Heart Failure. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)
Interventional
drug
Sponsor & Location
I.M. Sechenov First Moscow State Medical University
Timeline & Enrollment
Phase 4
Jan 01, 2021
Jan 01, 2022
Primary Outcome
admission to the intensive care unit due to worsening heart failure during the current hospitalization,death due to heart failure
Summary
The effect of sodium-glucose cotransporter type 2 inhibitors (SGLT2i) on the parameters of
 renal function in acute decompensation of chronic heart failure (CHF) compared to standard
 therapy will be analyzed. Based on the dynamics of the clinical condition, the duration of
 hospitalization, and blood biochemical parameters (creatinine, urea, uric acid, potassium,
 sodium, N-terminal pro-brain natriuretic peptide NT-proBNP) conclusions will be drawn about
 the possibility of using SGLT2i in this group of patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04778787
Non-Device Trial